Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Nancy Joseph-Ridge"'
Autor:
Jarrod P. Holmes, Nancy Joseph-Ridge, Lonnie D. Brent, Janine North, Julio A. Peguero, R. Campbell Garland, Stacia Young
Publikováno v:
Journal of Infusion Nursing
Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f3fd0fb2f5fbd2fdef7eb26b913e8f
https://pubmed.ncbi.nlm.nih.gov/34555839
https://pubmed.ncbi.nlm.nih.gov/34555839
Autor:
Nancy Joseph-Ridge, Ahmed Ayad, Janine North, Stacia Young-Wesenberg, Teresa Yang, Julio Antonio Peguero
Publikováno v:
Journal of Clinical Oncology. 39:e13508-e13508
e13508 Background: Oncology infusion centers are increasingly focused on improving operational efficiencies and patient satisfaction, while maintaining quality care. One key component is optimizing chair time, which has been especially important for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa69bf423a8a283090628113ce7ac103
https://doi.org/10.1200/jco.2021.39.15_suppl.e13508
https://doi.org/10.1200/jco.2021.39.15_suppl.e13508
Publikováno v:
The Journal of Clinical Pharmacology. 48:1014-1024
Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase, which is currently being developed for the management of hyperuricemia in patients with gout. The effect of age and gender on the pharmacokinetics, pharmacodynamics, and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43d6f187adcd46538873c012188ac7fa
https://doi.org/10.1177/0091270008322035
https://doi.org/10.1177/0091270008322035
Autor:
Pankaj A. Patel, Arthur K. Melkonian, Nathan L. Kleinman, Richard A. Brook, Nancy Joseph-Ridge, Truman J. Brizee, James E. Smeeding
Publikováno v:
Value in Health. 10(4):231-237
Objectives The goal of this analysis was to evaluate the impact of gout, a painful inflammatory arthritis condition, on an employed population's health-related work absence and objectively measured productivity output. Methods Payroll, demographic, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30082a51e5ce3027fe7eda65773495ec
Publikováno v:
The Journal of Clinical Pharmacology. 46:855-866
To evaluate the effect of febuxostat on the pharmacokinetics of indomethacin and naproxen and vice versa, 2 multiple-dose, 3-period crossover studies were performed in healthy subjects. In study 1, subjects received febuxostat 80 mg once daily, indom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d3cb5dfcd4d5cd3fe3e3a7559783ef1
https://doi.org/10.1177/0091270006289848
https://doi.org/10.1177/0091270006289848
Autor:
Truman J. Brizee, Nancy Joseph-Ridge, Pankaj A. Patel, James E. Smeeding, Arthur K. Melkonian, Richard A. Brook, Nathan L. Kleinman
Publikováno v:
Current Medical Research and Opinion. 22:1381-1389
To examine the economic burden of illness of gout in an employed population, quantifying the impact on employers annual health benefit costs for medical and prescription claims, sick leave, short- and long-term disability, and workers' compensation.A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09b76403e9f5e7c876e1df1585e2c4b2
https://doi.org/10.1185/030079906x112606
https://doi.org/10.1185/030079906x112606
Publikováno v:
Rheumatic Disease Clinics of North America. 32:359-382
A few clinical trials have evaluated therapeutic agents for crystal-associated arthropathy. Most of the studies are uncontrolled and observational. Management of patients who have acute crystal arthropathies usually is symptomatic with long-term mana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9ef75a504403092200d50b8be84433
https://doi.org/10.1016/j.rdc.2006.02.002
https://doi.org/10.1016/j.rdc.2006.02.002
Autor:
Michael Becker, Patricia A. MacDonald, William E. Palmer, Nancy Joseph-Ridge, W. Palo, H. R. Schumacher, N. L. Edwards
Publikováno v:
International Journal of Clinical Practice. 60:408-414
Measurements of tophus size can be important in monitoring the course of gout therapy, as tophus resolution is proposed as one measure of success of treatment. This multicentre study assessed the intra- and interreader reproducibility of quantitative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cfe054ba72ce92ca8ba09be9205fc11
https://doi.org/10.1111/j.1368-5031.2006.00853.x
https://doi.org/10.1111/j.1368-5031.2006.00853.x
Publikováno v:
Clinical Pharmacokinetics. 45:821-841
Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase currently being developed for the management of hyperuricemia in patients with gout.To investigate the pharmacokinetics, pharmacodynamics and safety of febuxostat over a range o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ed705226a5dfa4201d97a4cd5eb26b
https://doi.org/10.2165/00003088-200645080-00005
https://doi.org/10.2165/00003088-200645080-00005
Autor:
Patricia A. MacDonald, William A. Palo, Robert L. Wortmann, Laurent Vernillet, H. Ralph Schumacher, Nancy Joseph-Ridge, Denise Eustace, Michael Becker
Publikováno v:
Arthritis & Rheumatism. 52:916-923
Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac80016e92b4eceff169424c52a67d8
https://doi.org/10.1002/art.20935
https://doi.org/10.1002/art.20935